Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cixutumumab with Gemcitabine and Erlotinib in Metastatic Pancreatic Cancer
NCT00617708Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2008
- Primary completion
- Sep 2012
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cixutumumab in pancreatic cancer (PC), sponsored by National Cancer Institute. Started Mar 2008; status: completed.
02
Drugs
cixutumumab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00617708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00617708.